Login / Signup
Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
Riccardo Asero
Published in:
Allergy (2018)
Keyphrases
</>
drug induced
early onset
adverse drug